Marion E. Van Gelder-Meijer
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.
Journal: Cancers
Published: April 09, 2018
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Journal: Science advances
Published: July 26, 2016
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Journal: Cancer letters
Published: February 24, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Journal: Oncotarget
Published: February 12, 2016
A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.
Journal: PloS one
Published: August 25, 2015
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
Journal: Journal of cancer research and clinical oncology
Published: March 26, 2015
High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 07, 2014
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Journal: Hormones & cancer
Published: June 04, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
Journal: British journal of cancer
Published: January 21, 2014
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
Journal: Pharmacogenomics
Published: August 12, 2011
Last Updated: 09/26/2026